Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed amning

Janusmed amning – Xolair

Janusmed amning tillhandahåller generella rekommendationer om huruvida ett friskt fullgånget spädbarn kan ammas när modern använder olika läkemedel. Observera att prematura och/eller sjuka spädbarn alltid kräver särskilda överväganden. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed amning och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Omalizumab Testmiljö

Omalizumab

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Saito J, Yakuwa N, Sandaiji N, Uno C, Yagishita S, Suzuki T et al. Omalizumab concentrations in pregnancy and lactation: A case study. J Allergy Clin Immunol Pract. 2020;8(10):3603-3604.

  2. Ensina LF, Cusato-Ensina AP, Camelo-Nunes IC, Solé D. Omalizumab as Third-Line Therapy for Urticaria During Pregnancy. J Investig Allergol Clin Immunol. 2017;27(5):326-327.

  3. González-Medina M, Curto-Barredo L, Labrador-Horrillo M, Giménez-Arnau A. Omalizumab use during pregnancy for chronic spontaneous urticaria (CSU): report of two cases. J Eur Acad Dermatol Venereol. 2017;31(5):e245-e246.

  4. Losappio LM, Mirone C, Schroeder JW, Scibilia J, Balossi L, Pastorello EA. Omalizumab Use in Chronic Spontaneous Urticaria during Pregnancy and a Four Years' Follow-Up: A Case Report. Case Rep Dermatol. 2020;12(3):174-177.

  5. Majou D, Moreira B, Martin C, Chhun S, Treluyer JM, Tsatsaris V et al. Safety of Omalizumab During Pregnancy and Breast-Feeding With Assessment of Placental Transfer: A Case Report. Allergy Asthma Immunol Res. 2021;13(3):515-516.

  6. Liao SL, Yu M, Zhao ZT, Maurer M. Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy. Front Immunol. 2021;12(0):652973.

  7. López Leon, S, Kaufman DG, Howard M, et al. Safety outcomes among infants exposed to omalizumab via breastfeeding: Results from the Xolair Pregnancy Registry (Expect). Pharmacoepidemiol Drug Saf 2019;28 (Suppl 2):374-5. Abstract.

  1. Saito J, Yakuwa N, Sandaiji N, Uno C, Yagishita S, Suzuki T et al. Omalizumab concentrations in pregnancy and lactation: A case study. J Allergy Clin Immunol Pract. 2020;8(10):3603-3604.
  2. Ensina LF, Cusato-Ensina AP, Camelo-Nunes IC, Solé D. Omalizumab as Third-Line Therapy for Urticaria During Pregnancy. J Investig Allergol Clin Immunol. 2017;27(5):326-327.
  3. González-Medina M, Curto-Barredo L, Labrador-Horrillo M, Giménez-Arnau A. Omalizumab use during pregnancy for chronic spontaneous urticaria (CSU): report of two cases. J Eur Acad Dermatol Venereol. 2017;31(5):e245-e246.
  4. Losappio LM, Mirone C, Schroeder JW, Scibilia J, Balossi L, Pastorello EA. Omalizumab Use in Chronic Spontaneous Urticaria during Pregnancy and a Four Years' Follow-Up: A Case Report. Case Rep Dermatol. 2020;12(3):174-177.
  5. Majou D, Moreira B, Martin C, Chhun S, Treluyer JM, Tsatsaris V et al. Safety of Omalizumab During Pregnancy and Breast-Feeding With Assessment of Placental Transfer: A Case Report. Allergy Asthma Immunol Res. 2021;13(3):515-516.
  6. Liao SL, Yu M, Zhao ZT, Maurer M. Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy. Front Immunol. 2021;12(0):652973.
  7. López Leon, S, Kaufman DG, Howard M, et al. Safety outcomes among infants exposed to omalizumab via breastfeeding: Results from the Xolair Pregnancy Registry (Expect). Pharmacoepidemiol Drug Saf 2019;28 (Suppl 2):374-5. Abstract.

Innehållet senast uppdaterat 11/7/2024